-
Key information relating to the potential subsequent repair offering to be carried out by Ultimovacs ASA
-
Ultimovacs ASA – Mandatory notification of trade
-
ULTIMOVACS ANNOUNCES AGREEMENT TO COMBINE ITS BUSINESS WITH ZELLUNA IMMUNOTHERAPY AND INTENTION TO LAUNCH FULLY COMMITTED PRIVATE PLACEMENT
-
Ultimovacs ASA Reports Third Quarter 2024 Financial Results and Provides General Business Update
-
Ultimovacs ASA: Invitation to third quarter 2024 results webcast presentation
-
Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv
-
Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Trial Investigating UV1 Combined with Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer
-
Ultimovacs Announces Updated Data Analysis on UV1 Phase II NIPU Trial in Mesothelioma at ESMO 2024
-
Ultimovacs Announces Updated Data Analysis on UV1 Phase II NIPU Trial in Mesothelioma at ESMO 2024
-
Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provides General Business Update
